Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ABL Diagnostics's Enterprise Value is €43.68 Mil.
ABL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.40 Mil. Therefore, ABL Diagnostics's EV-to-EBIT ratio for today is 108.38.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ABL Diagnostics's Enterprise Value is €43.68 Mil.
ABL Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.01 Mil. Therefore, ABL Diagnostics's EV-to-EBITDA ratio for today is 43.12.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ABL Diagnostics's Enterprise Value is €43.68 Mil.
ABL Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €6.95 Mil. Therefore, ABL Diagnostics's EV-to-Revenue ratio for today is 6.28.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, ABL Diagnostics's Enterprise Value is €43.68 Mil.
ABL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.72 Mil. Therefore, ABL Diagnostics's EV-to-FCF ratio for today is 61.09.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
ABL Diagnostics (XPAR:ABLD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
ABL Diagnostics's current Enterprise Value is €43.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.40 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
ABL Diagnostics's current Enterprise Value is €43.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.01 Mil.
ABL Diagnostics's current Enterprise Value is €43.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €6.95 Mil.
ABL Diagnostics's current Enterprise Value is €43.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €1.51 Mil.
ABL Diagnostics's current Enterprise Value is €43.68 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics Enterprise Value Related Terms
ABL Diagnostics Enterprise Value Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Enterprise Value Comparison
For the Health Information Services subindustry, ABL Diagnostics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Enterprise Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
ABL Diagnostics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a Enterprise Value of €43.68 Mil as of Jul. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ABL Diagnostics and its competitors.
Is ABL Diagnostics' Enterprise Value too high?
ABL Diagnostics' current Enterprise Value is €43.68 Mil. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Enterprise Value compare to VEEV and BTSG?
ABL Diagnostics' Enterprise Value of €43.68 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Enterprise Value is €43.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Enterprise Value is €43.68 Mil. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Enterprise Value is €43.68 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Enterprise Value: €43.68 Mil
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
